GC Cell Receives Approval for Amendment of Phase 1 Clinical Trial Plan for GCC2005, Adding Arms for Patient Convenience and Dose Optimization
GC Cell received approval from the Ministry of Food and Drug Safety on July 20, 2026, for an amendment to the domestic Phase 1 clinical trial plan for GCC2005, a treatment for relapsed or refractory NK and T-cell malignancies.
The amendment adds a single-dose arm in the dose expansion phase to improve patient convenience and determine optimal dosing, along with a backfill cohort to collect additional data for the future Phase 2 recommended dose.
The trial will enroll up to 53 patients across six hospitals in South Korea, with an expected completion date of August 14, 2027. Statistically, the probability of final drug approval is about 10%, indicating significant investment risk.
This disclosure is an administrative milestone for a clinical trial plan amendment and has no direct financial impact such as capital changes or dividends.
[AI Summary]GC Cell's approval of the GCC2005 Phase 1 trial amendment is a procedural step for trial optimization with no short-term financial effect, but the inherent low success rate of drug development retains investment risk. The stock price impact is assessed as neutral.
KOSDAQ Filing Information
Major Management Matters Related to Investment Decision (Approval of Change in Clinical Trial Plan) (Approval of Change in Domestic Phase 1 Clinical Trial Plan of GCC2005)